NAD+ research and evidence overview

The honest verdict: NAD+ biology is well-documented, and precursor supplements reliably raise blood NAD+ in people — but the human trials published so far have mostly failed to convert that biochemical change into measurable improvements in body composition, insulin sensitivity, or mitochondrial function. Almost none of the marketed anti-aging claims rest on a completed, adequately powered clinical outcome trial, and the intravenous NAD+ infusions sold in clinics have essentially no controlled trial evidence at all.

Nicotinamide adenine dinucleotide is a redox cofactor required for glycolysis, the citric acid cycle, and oxidative phosphorylation, and a consumed substrate for sirtuins, PARPs, and CD38. The 2021 Nature Reviews Molecular Cell Biology review by Covarrubias and colleagues, NAD+ metabolism and its roles in cellular processes during ageing, maps the three biosynthetic routes (kynurenine, Preiss-Handler, and salvage pathways) and the evidence that tissue NAD+ declines with age in animals and humans, with links to metabolic dysfunction, inflammation, neurodegeneration, and senescence.

That review is a synthesis of mechanism, not a trial. Its own conclusion is cautious: the authors state that much remains unknown about how NAD+ influences human health and whether NAD+ repletion is safe and beneficial in ageing humans.

Most human data concern oral precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — rather than NAD+ itself.

In a 2×6-week randomized, double-blind, placebo-controlled crossover trial in healthy middle-aged and older adults (n=30 completing; Nature Communications, 2018), 1,000 mg/day NR was well tolerated and roughly doubled whole-blood NAD+ ( Martens et al.). The physiological readouts were exploratory: a suggestion of reduced systolic blood pressure and aortic stiffness in participants with elevated baseline values, which the authors framed as a hypothesis for future trials rather than a demonstrated benefit.

The Covarrubias review summarizes the same pattern across other NR studies in older and obese adults: NAD+ levels rose, but participants showed no weight loss, no improvement in insulin sensitivity, and no enhanced mitochondrial function. Raising the biomarker is not the same as changing the outcome.

Clinic-administered intravenous NAD+ is the form most heavily marketed for energy, addiction recovery, and "cellular repair," and it is the form with the thinnest published evidence. Pharmacokinetic and outcome data from randomized IV trials are scarce; the precursor literature above cannot be transferred to it, because the dose, route, and metabolic handling all differ. Anyone evaluating an IV NAD+ claim is looking at extrapolation from oral-precursor and preclinical work rather than direct evidence.

NAD+ and NMN are not FDA-approved drugs for any indication. NMN's status as a dietary-supplement ingredient has been contested in the United States because it has been investigated as a drug. NAD+ appears on FDA lists of substances raising concerns for compounding. None of this is a verdict on safety — it reflects that no sponsor has completed the trial package an approval requires.

• Ask whether the endpoint was a biomarker (blood NAD+) or an outcome (strength, insulin sensitivity, walking distance). Most positive headlines describe the former.
• Check the molecule: results for oral NR do not automatically apply to NMN, and neither applies to IV NAD+.
• Check the species. Much of the striking longevity data comes from mice and worms, where NAD+ decline can be manipulated far more cleanly than in people.
• Check duration. Six-to-twelve-week trials cannot answer questions about aging trajectories measured in decades.